AB0710 MIXED RESPONSE TO TOFACITINIB IN INDIAN PATIENTS WITH REFRACTORY TAKAYASU ARTERITIS: A MULTI-CENTER STUDY

Background Treatment of patients with Takayasu arteritis (TAK) is challenging in-spite the use conventional cytotoxic agents and biologics. Tofacitinib has been reported to be effective in inducing maintaining remission around 80% refractory TAK [1]. Objectives To assess efficacy safety tofacitinib Indian TAK. Methods In this retrospective study, medical records consecutive being treated either originator or generic at 4 centres India were studied. Details regarding demographics, clinical presentation, disease duration, Activity score (ITAS), laboratory markers angiography treatment response recorded. The was considered active if patient had evidence activity any two following three domains: new symptoms as evidenced by ITAS >1; persistently raised C-reactive protein (CRP) for 2 visits; areas arterial wall thickening uptake 18FDG PETCT respectively. Good defined absence least 3 above-mentioned domains. contrast, presence carotidynia narrowing standalone indicators activity. follow up imaging, a rise CRP from baseline visit on occasions also disease. data presented mean± SD median (Interquartile range) according distribution data. Fischer’s exact test Mann Whitney used compare parameters between good no treatment. Results Twenty-seven (24, 88.9% females; age 30.4 ± 8.13 years) duration 48 (20-72) months included. At diagnosis, 13 (48.1%), 6 (22.2%), 15 (55.6%) 7 (25.9%) constitutional symptoms, carotidynia, ischemia features aortic regurgitation All while all except 1, received (1-4) lines immunosuppressants including biologics 16 (59.3%). prior systemic steroids. indication switching clinical, imaging wise 19, 17 ESR, CRP, steroid dose initiation 46 (25-72) mm/1 st hr, 25 (16.5-44) mg/L, 0 (0-2) 7.5 (5-10) mg/day 10 (5-12) months, clinically stable observed 18 (72%), normalisation 9 (36%), decrease 8 (32%) non-progression lesions (available patients) patients. Overall, 14 (51.9%) domains classified responders. responders trended have significantly higher compared non-responders (median: 60 (41-96) vs 27 (6-63) months), p= 0.054. None other differentiated groups. Four discontinued drug due side effects one sudden death within tofacitinib. Conclusion modest difficult treat Further multi-ethnic studies are required ascertain its effectiveness References [1]Kong X, Sun Y, Dai Wang L, Ji Z, Chen H, Jin Ma Jiang L. versus methotrexate arteritis: prospective observational study. Ann Rheum Dis. 2022 Jan;81(1):117-123. Acknowledgements: NIL. Disclosure Interests Declared.